DOCSLIB.ORG

COVID-19 Vaccine Candidates Information Updated: 03/17/2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Vaccine Candidates Information Updated: 03/17/2021 COVID-19 Vaccine Candidates Information Updated: 03/17/2021 Manufacturer Vaccine Storage Doses Handling + Efficacy Timeline of Fed Govt Technology/Type Requirements Administration Development Contract Pfizer/BioNTech mRNA vaccine Distributed at -80 Original Mix with Reported 95% EUA granted 100 mil to -60 ᵒC and can protocol for 5 diluent on site. efficacy (Press Dec. 11, 2020. doses in 2 dose series 21 be stored at this doses/vial in Release) original days apart temperature until protocol. Once one vial Vaccination purchase. expiry date. Changed to 6 removed from Efficacy reduced began Dec. 14, doses per vial. pizza box, the towards UK and 2020 Additional May be stored entire box is South African 100 mil -25ᵒC to -15ᵒC FDA advises to considered as Variants (Press January 2021 purchased for two weeks use all available having started Release). Pfizer completed Dec.23, cumulatively with doses, now to thaw. enrolling children 2020 to one return to -80 considered 6 ages 12+ in Phase have by to -60 ᵒC. (may be able to May be III trial. They July 2021. get 7). transported at hope for data by Stable for 5 hours: -25ᵒC to - summer 2021 120 2-8 ᵒC Minimum order: 15ᵒC. (here). million 1024 doses total by Stable for up to (based on 5 Phase I clinical the end of 30 days in doses per vial) trial to March shipping box if dry investigate the 2021 and ice is maintained safety and another and 5 days after efficacy of a 3rd 180 at 2-8 ᵒC for a booster shot of million by total of 35 days. Pfizer COVID-19 the end of vaccine began July. February 25, 2021 (here). Recruiting pregnant women for a Phase II/III trial (here). 1 Moderna mRNA vaccine Lasts for 6 10 doses/vial No dilution or Reported 94.1% EUA granted 100 mil months at -25ᵒC special efficacy (Press Dec. 18, 2020. doses in 2 dose series 28 to -15ᵒC Minimum order handling on Release) original days apart is 10 vials: 100 site. Vaccination purchase. Can be stored for doses Efficacy reduced began Dec. 30 days 2-8 ᵒC towards UK and 21,2020. Additional prior to first use South African 100 mil Variants (Press March 10, 2021 purchased Good for 12 hours Release). began trial to on Dec. at 8-25ᵒC evaluate a 11, 2020 COVID-19 to have by Vaccine is viable vaccine booster July 2021. for 6 hours once for the South vial is pierced African variant Total 100 (Press Release) (here). million by the end of March 15, 2021 March began Phase I 2021 and trial for next another generation 100 COVID-19 million by vaccine mRNA- the end of 1283 (here). July 2021. March 16, 2021 first patients doses in Phase II/III clinical trial enrolling children aged 6 months to 12 years (here). Janssen (+ 1 dose Storage at 2-8 ᵒC 5 dose/vial of No Reported 66% EUA granted 20 million Johnson & Adenovirus for up to three 0.5mL dose preservative in efficacy globally February 27, by the end Johnson) Vector based months vial, no and 72% within 2021. of March, vaccine 10 vials per reconstitution the US. 85% another carton, 48 effective in 100 2 After first use cartons per required at preventing severe Vaccination million by lasts for 6 hours shipper = 2400 site. disease. These began March 1, the end of at 2-8 ᵒC doses per lower efficacies 2021. July shipper Do not are attributed to Expected to vigorously the study being remain stable for Minimum order shake, but done while SARS- up to two years at 100 doses. otherwise can CoV-2 variants -20° C. handle driving were on bumpy predominant in roads or being study areas. jostled. AstraZeneca and Adenovirus Storage at 2-8 ᵒC No dilution or 90% reported for A phase III trial in 300 mil Oxford Vector based, 2 for 6 months reconstitution the group who the US of 30,000 doses doses received a half participants is After first dose and then a expected to yield puncture, store full dose. clarifying results up to 6 hours at on the best dose room 60% reported for regimen. temperature or the group who up to 48 hours at received 2 full AstraZeneca 2-8 ᵒC doses (read more expects data here) from US Phase III clinical trial to be Feb 2, 2021: available soon reported single and file for EUA dose 76% efficacy in April. and after second dose given 12 Approved in UK, weeks later was Argentina, Brazil, 82.4%. Data also India, and suggests reduced COVAX. Use transmission in suspended in addition to Germany, France, prevention of Italy, Norway, symptoms (here) Denmark, 3 Iceland, Netherlands. NOVAVAX Protein-based Storage at 2-8 ᵒC 10 doses/vial Co-formulated Final analysis of Phase III trial in 110 vaccine candidate Handling at room with adjuvant. UK trial confirms US began Dec. million containing temp: 25 ᵒC Minimum order: No mixing 96.4% efficacy 28, 2020 with purchased antigen derived Very stable under assume 100 required. against original goal of enrolling by the US from the stress conditions, doses COVID-19 and 30,000 coronavirus spike will utilize 86.3% against participants (S) protein. standard cold B.117 (UK) strain. (here). chain Complete analysis 2 dose series from Phase 2b Rolling Review trial in South with FDA going Africa reports on now. 55.4% efficacy against B1.351 Novavax is strain. Across hopeful to apply both trials 100% for EUA in May protection against using UK data, severe disease, otherwise EUA hospitalization, application will and death (here). occur summer 2021 when the US Phase III trial ends. MEDICAGO Plant produced Stable at 4-8 ᵒC 10 doses/vial 1 dose of Phase III trial Coronavirus-Like product + 1 began March 16, Particle COVID- Minimum order: dose of 2021 (here). 19 vaccine assume 100 adjuvant candidate doses Mixed on site (CoVLP) is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs). 4 2 dose series 21 days apart INOVIO INO-4800 DNA Stable at 25 ᵒC for 10 doses/vial CELLECTRA Phase 1 data vaccine (2-dose >1 year, hand-held published on series) 37 ᵒC for >2 Minimum order: smart device June 30, 2020. months assume 100 uses electrical In buffer, 2-8 ᵒC doses pulse to deliver Phase II clinical for >5 years vaccine trial started Dec. 2020. FDA approval of CELLECTRA Phase III trial device began by the end continues to of the second delay start of quarter of 2021 PhaseII/III clinical trial Sanofi Pasteur + recombinant Storage 2-8 ᵒC for 10 doses of Recombinant Began Phase I/II 100 mil GlaxoSmithKline protein product and product/vial vaccine on Sept. 3, 2020. doses adjuvanted adjuvant 10 doses product + vaccine (2 dose adjuvant/vial adjuvant Disappointing + optional series) Administration: phase I/II results, purchase 25 ᵒC Minimum order: Mixed on site. Phase 2b trial of 500 mil assume 100 with modified doses doses vaccine product began February 22, 2021 (here). Sanofi Pasteur + mRNA vaccine Storage at -20 ᵒC Minimum order: Phase I/II trial TranslateBio MRT5500 assume 100 initiated March doses 12, 2021 (here). 1 or 2-dose series, 21 days apart being evaluated MERCK + IAVI DISCONTINUED (V590) MERCK #2 DISCONTINUED (V591) 5 Sources: • https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html • https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html • https://www.reuters.com/article/health-coronavirus-astrazeneca-vaccine/u-s-astrazeneca-vaccine-trial-will-clear-confusion-on-how-well-it- works-u-s-scientist-idUSKBN28H1YL • http://s23.q4cdn.com/479936946/files/doc_news/INOVIO-and-Advaccine-Announce-First-Dosing-of-Subject-in-Phase-2-Clinical-Trial-for- COVID-19-DNA-Vaccine-Candidate-INO-4800-in-China-2020.pdf • https://www.medicago.com/en/newsroom/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of-adjuvanted-covid-19-vaccine- candidate/ • https://www.sanofi.com/en/about-us/our-stories/sanofi-s-response-in-the-fight-against-covid-19 • https://www.ox.ac.uk/news/2021-02-02-oxford-coronavirus-vaccine-shows-sustained-protection-76-during-3-month-interval • https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Villafana.pdf • https://www.reuters.com/article/us-health-coronavirus-inovio-pharma/inovio-expects-to-begin-late-stage-covid-19-vaccine-study-in-second- quarter-idUSKBN2991HR • https://www.nytimes.com/2021/02/12/health/covid-vaccines-children.html • https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine • https://www.reuters.com/article/us-novavax-results/novavax-covid-19-shot-could-be-cleared-for-u-s-use-by-may-ceo-idUSKCN2AT3MD • https://www.reuters.com/article/us-health-coronavirus-astrazeneca-usa/exclusive-u-s-green-light-for-astrazeneca-vaccine-could-come-in- april-independent-monitors-assessing-data-us-official-idUSKBN2B723D 6 .
Load more

Recommended publications
  • An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages
    International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli­ cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages.
    [Show full text]
  • Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • Curevac O Celonic Wi
    Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • CureVac o Celonic will manufacture 100 million doses of CureVac’s vaccine at its plant in Heidelberg, Germany, providing bulk substance for 50 million doses by the end of 2021. (press release) o Novartis will manufacture CureVac’s vaccine. (press release) o GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. (press release) o Rentschler Biopharma SE will manufacture CureVac’s vaccine. (press release) o Bayer will support the further development, supply and key territory operations of CureVac’s vaccine candidate. (press release) o Fareva will dedicate a manufacturing plant in France to the fill and finish of CureVac’s vaccine. (press release) o Wacker Chemie AG will manufacture CureVac’s vaccine candidate at its Amsterdam site. (press release) o CureVac will collaborate with Tesla Grohmann Automation to develop an RNA printer that works like a mini-factory and can produce such drugs automatically. (press release) • Moderna o Samsung Biologics will provide large scale, commercial fill-finish manufacturing for Moderna’s vaccine in South Korea. (press release) o Baxter International will provide fill/finish services and supply packaging for Moderna. (press release) o Sanofi will manufacture 200 million doses of Moderna’s COVID-19 vaccine starting in September 2021. (press release) o Rovi will produce bulk substance for Moderna’s COVID-19 vaccine, expanding an agreement between the companies.
    [Show full text]
  • COVID-19 Situation Report 210
    For citation: Centre for Infectious Disease Epidemiology and Research-NUS. COVID-19 Situation Report 210. 27 August 2020 Aug 27 COVID-19 Situation Report 210 Centre for Infectious Disease Epidemiology and Research (CIDER) For citation: Centre for Infectious Disease Epidemiology and Research-NUS. COVID-19 Situation Report 210. 27 August 2020 i. Background In December, China notified the World Health Organization (WHO) of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, previously known as 2019-nCoV and now called SAR-CoV-2; The new name of the disease has also been termed COVID-19, as of 11th February 2020. Although the virus is presumed zoonotic in origin, person-to-person spread is evident. Screening of travellers, travel bans and quarantine measures are being implemented in many countries. Despite these precautions, it is anticipated that more cases will be seen both inside China and internationally. The WHO declared the outbreak of COVID-19 constitutes a Public Health Emergency of International Concern on 30 January. On 11 March, 2020, WHO declared the coronavirus outbreak a pandemic as the global death toll rose above 4,600 and the number of confirmed cases topped 125,000. This report aims to update Global Risk Assessment, Global Epidemiology, Quarantine Orders, Travel Ban/Advisory by countries, WHO’s and CDC’s Guidance and Protocols and Scientific publication on a daily basis. New updates in the tables are bolded. 1 | P a g e Centre for infectious di sease epidemiology and research For citation: Centre for Infectious Disease Epidemiology and Research-NUS.
    [Show full text]
  • Vaccins Contre La Covid-19 Et Utilisation De Cellules D'origine Fœtale
    Vaccins contre la Covid-19 et utilisation de cellules d’origine fœtale : un questionnement éthique pour les chrétiens. Dr Michel Cambrelin La pandémie Covid-19 due au nouveau Coronavirus SARS-CoV-2 n’épargne pas nos sociétés occidentales, qui sont fortement ébranlées malgré leur richesse et leur technologie, et notre pays ne fait pas exception1. Après les échecs successifs des tentatives de contenir cette épidémie, la vaccination nous est présentée comme la planche de salut. Cette vaccination a pour principe de présenter à l’organisme receveur des éléments inoffensifs appartenant au virus, ce qui va lui permettre de fabriquer des anticorps prêts à le défendre lorsque le virus essaiera de le pénétrer. Pour ces vaccins différentes techniques ont été utilisées, qui pour certaines sont assez nouvelles, que nous expliquerons plus loin. De multiples questions et rumeurs circulent sur les vaccins Covid en particulier à ARN messager (ARNm), auxquelles l’OMS2 et la Société de Pathologie Infectieuse de Langue Française3 ont apporté leurs réponses. Bien que les Français y semblaient réticents au départ, une politique de vaccination croissante se met en place, dont on critique maintenant la lenteur du démarrage. Cependant une autre question interpelle les chrétiens, respectueux de la vie humaine constituant un don de Dieu dès la conception4, question qui n’est pas abordée dans les médias ni dans les recommandations scientifiques : certains vaccins contre la Covid auraient été élaborés à l’aide de cellules de fœtus avortés ! Nous allons tenter d’apporter les éléments de réponse nécessaires à cette question, qui semble ignorée du débat public, sans aborder les autres questions d’innocuité et d’efficacité de ces vaccins qui ont aussi leur importance éthique.
    [Show full text]
  • Outcome Reporting Bias in COVID-19 Mrna Vaccine Clinical Trials
    medicina Perspective Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials Ronald B. Brown School of Public Health and Health Systems, University of Waterloo, Waterloo, ON N2L3G1, Canada; [email protected] Abstract: Relative risk reduction and absolute risk reduction measures in the evaluation of clinical trial data are poorly understood by health professionals and the public. The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects the interpretation of vaccine efficacy. The present article uses clinical epidemiologic tools to critically appraise reports of efficacy in Pfzier/BioNTech and Moderna COVID-19 mRNA vaccine clinical trials. Based on data reported by the manufacturer for Pfzier/BioNTech vaccine BNT162b2, this critical appraisal shows: relative risk reduction, 95.1%; 95% CI, 90.0% to 97.6%; p = 0.016; absolute risk reduction, 0.7%; 95% CI, 0.59% to 0.83%; p < 0.000. For the Moderna vaccine mRNA-1273, the appraisal shows: relative risk reduction, 94.1%; 95% CI, 89.1% to 96.8%; p = 0.004; absolute risk reduction, 1.1%; 95% CI, 0.97% to 1.32%; p < 0.000. Unreported absolute risk reduction measures of 0.7% and 1.1% for the Pfzier/BioNTech and Moderna vaccines, respectively, are very much lower than the reported relative risk reduction measures. Reporting absolute risk reduction measures is essential to prevent outcome reporting bias in evaluation of COVID-19 vaccine efficacy. Keywords: mRNA vaccine; COVID-19 vaccine; vaccine efficacy; relative risk reduction; absolute risk reduction; number needed to vaccinate; outcome reporting bias; clinical epidemiology; critical appraisal; evidence-based medicine Citation: Brown, R.B.
    [Show full text]
  • Ethics of Vaccine Research
    COMMENTARY Ethics of vaccine research Christine Grady Vaccination has attracted controversy at every stage of its development and use. Ethical debates should consider its basic goal, which is to benefit the community at large rather than the individual. accines truly represent one of the mira- include value, validity, fair subject selection, the context in which it will be used and Vcles of modern science. Responsible for favorable risk/benefit ratio, independent acceptable to those who will use it. This reducing morbidity and mortality from sev- review, informed consent and respect for assessment considers details about the pub- eral formidable diseases, vaccines have made enrolled participants. Applying these princi- lic health need (such as the prevalence, bur- substantial contributions to global public ples to vaccine research allows consideration den and natural history of the disease, as health. Generally very safe and effective, vac- of some of the particular challenges inherent well as existing strategies to prevent or con- cines are also an efficient and cost-effective in testing vaccines (Box 1). trol it), the scientific data and possibilities way of preventing disease. Yet, despite their Ethically salient features of clinical vac- (preclinical and clinical data, expected brilliant successes, vaccines have always been cine research include the fact that it involves mechanism of action and immune corre- controversial. Concerns about the safety and healthy subjects, often (or ultimately) chil- lates) and the likely use of the vaccine (who untoward effects of vaccines, about disturb- dren and usually (at least when testing effi- will use and benefit from it, safety, cost, dis- ing the natural order, about compelling indi- cacy) in very large numbers.
    [Show full text]
  • COVID-19 Vaccine Trials
    COVID-19 VACCINE TRIALS SUMMARY OF PFIZER AND MODERNA COVID-19 VACCINE RESULTS Some of the most common concerns voiced involve the A review of unblinded reactogenicity data from the speed with which these vaccines were developed and final analysis which consisted of a randomized subset whether they are safe or not. How were the companies of at least 8,000 participants 18 years and older in able to get these vaccines developed and ready for the phase 2/3 study demonstrates that the vaccine distribution so fast? Were they tested in persons who was well tolerated, with most solicited adverse events are most vulnerable? Are the vaccines safe? resolving shortly after vaccination. Even though COVID-19 vaccines were developed at While the vaccine was well tolerated overall, and side an extraordinary speed, companies were required effects lasted for only a day or two, persons taking to take all of the regulatory and operational steps the vaccine should be aware that the side effects normally required for all vaccine trials, so none of are more than is seen in general for the flu vaccine these steps were skipped. What did occur that does and be prepared for them. Most side effects were not normally occur was some upfront financial mild to moderate and included injection-site pain, assistance from the federal government (Moderna redness and swelling at the injection site, fatigue/ accepted, Pfizer declined) and federal regulatory tiredness, headache, chills, muscle pain, and joint agencies working closely with the companies, pain. “Severe” side effects, defined as those that providing near real-time data with companies prevent persons from continuing daily activities were receiving review and advice more quickly.
    [Show full text]
  • 1 Title: Interim Report of a Phase 2 Randomized Trial of a Plant
    medRxiv preprint doi: https://doi.org/10.1101/2021.05.14.21257248; this version posted May 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 Title: Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle 2 Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older 3 Authors: Philipe Gobeil1, Stéphane Pillet1, Annie Séguin1, Iohann Boulay1, Asif Mahmood1, 4 Donald C Vinh 2, Nathalie Charland1, Philippe Boutet3, François Roman3, Robbert Van Der 5 Most4, Maria de los Angeles Ceregido Perez3, Brian J Ward1,2†, Nathalie Landry1† 6 Affiliations: 1 Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 7 3V9; 2 Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, 8 QC H4A 3J1; 3 GlaxoSmithKline Biologicals SA (Vaccines), Avenue Fleming 20, 1300 Wavre, 9 Belgium; 4 GlaxoSmithKline Biologicals SA (Vaccines), rue de l’Institut 89, 1330 Rixensart, 10 Belgium; † These individuals are equally credited as senior authors. 11 * Corresponding author: Nathalie Landry, 1020 Route de l’Église, Bureau 600, Québec, Qc, 12 Canada, G1V 3V9; Tel. 418 658 9393; Fax. 418 658 6699; [email protected] 13 Abstract 14 The rapid spread of SARS-CoV-2 globally continues to impact humanity on a global scale with 15 rising morbidity and mortality. Despite the development of multiple effective vaccines, new 16 vaccines continue to be required to supply ongoing demand.
    [Show full text]
  • Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines
    Review Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines Puna Maya Maharjan 1 and Sunghwa Choe 2,3,* 1 G+FLAS Life Sciences, 123 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si 28161, Korea; punamaya.maharjan@gflas.com 2 G+FLAS Life Sciences, 38 Nakseongdae-ro, Gwanak-gu, Seoul 08790, Korea 3 School of Biological Sciences, College of Natural Sciences, Seoul National University, Gwanak-gu, Seoul 08826, Korea * Correspondence: [email protected] Abstract: The prevalence of the coronavirus disease 2019 (COVID-19) pandemic in its second year has led to massive global human and economic losses. The high transmission rate and the emergence of diverse SARS-CoV-2 variants demand rapid and effective approaches to preventing the spread, diagnosing on time, and treating affected people. Several COVID-19 vaccines are being developed using different production systems, including plants, which promises the production of cheap, safe, stable, and effective vaccines. The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco- produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak. Currently, two plant-based COVID-19 vaccine candidates, coronavirus virus-like particle (CoVLP) and Kentucky Bioprocessing (KBP)-201, are in clinical trials, and many more are in the preclinical stage. Interim phase 2 clinical Citation: Maharjan, P.M.; Choe, S. trial results have revealed the high safety and efficacy of the CoVLP vaccine, with 10 times more Plant-Based COVID-19 Vaccines: neutralizing antibody responses compared to those present in a convalescent patient’s plasma.
    [Show full text]
  • Information & Consent Form
    INFORMATION & CONSENT FORM RESEARCH TITLE: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older SHORT TITLE: A randomized controlled study, assessing the safety and immunogenicity of a COVID-19 vaccine in adults PROTOCOL NUMBER: CP-PRO-CoVLP-021 RESEARCHERS: Principal Investigator: Dr. Scott Halperin, Pediatric Infectious Disease Specialist, IWK Health Centre Co-Investigators: Dr. Joanne Langley, Pediatric Infectious Disease Specialist, IWK Health Centre Dr. Jeannette Comeau, Pediatric Infectious Disease Specialist, IWK Health Centre FUNDER: Medicago R&D Inc. SPONSOR: Medicago R&D Inc. 1020 route de l’Église, bureau 600 Québec (QC), Canada G1V 3V9 Introduction You are being asked to take part in this research study to assess the safety and ability of an investigational study vaccine to generate an immune response against the virus causing COVID-19 disease. You can decide if you want to take part in this study or not. Your choice will not change the quality of care that you will receive outside of this study. Please take time to read the following information about the study. Feel free to ask the study staff any questions that you may have. Informed consent means agreeing to take part in a research study, but only when you fully understand what this means for you. You sign this informed consent form only if you agree to take part in this study. Signing the form shows that you have understood what this means for you and that you want to take part.
    [Show full text]
  • Periodic Update on AEFI
    CONSOLIDATED REGIONAL AND GLOBAL INFORMATION ON ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI) AGAINST COVID-19 AND OTHER UPDATES WASHINGTON, DC Updated: 31 March 2021 1 OFFICIAL REPORTS ON PHARMACOVIGILANCE PROGRAMS CANADA § As of 19 March 2021, 3,729,312 doses of the Pfizer-BioNTech, Moderna, and Covishield vaccines had been administered. § A total of 2,530 individual reports of one or more adverse events (0.068% of doses administered) were reported. Of these, 320 were considered serious events (0.009% of doses administered), with anaphylaxis being the most frequently reported. § There were a total of 7,397 adverse events following immunization (AEFI) (consisting of 2,530 reports of one or more events), mostly non-serious adverse events, such as injection-site reactions, partesia, itching, hives, headache, hyposthesia, and nausea. Only 0.8% of cases corresponded to anaphylaxis (59 cases, or 15.8 cases per million doses administered). § Most adverse events reported were among women, and in people between the ages of 18 and 49, these being the groups prioritized for vaccination § A total of 24 reported adverse events were identified as post-vaccination deaths. After medical review, it was determined that 13 of these deaths were not linked to administration of the COVID-19 vaccine, while the other 11 are still under investigation. Link: https://health-infobase.canada.ca/covid-19/vaccine-safety/ UNITED STATES § Nearly 126 million doses of the Pfizer-BioNTech and Moderna vaccines were administered between 14 December 2020 and 29 March 2021. § The Vaccine Adverse Event Reporting System (VAERS) received 2,509 reports of deaths (0.0019% of doses administered) that have not been linked to the vaccine.
    [Show full text]
  • Considerations for the Design of Vaccine Efficacy Trials During Public Health Emergencies
    bioRxiv preprint doi: https://doi.org/10.1101/261875; this version posted February 13, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Considerations for the design of vaccine efficacy trials during public health emergencies Natalie E. Dean1*, Pierre-Stéphane Gsell2, Ron Brookmeyer3, Victor De Gruttola4, Christl A. Donnelly5, M. Elizabeth Halloran6,7, Momodou Jasseh8, Martha Nason9, Ximena Riveros2, Conall Watson10, Ana Maria Henao-Restrepo2, Ira M. Longini, Jr.1* 1Department of Biostatistics, University of Florida, Gainesville, FL, USA. 2World Health Organization, Geneva, Switzerland. 3Department of Biostatistics, University of California, Los Angeles, CA, USA. 4Department of Biostatistics, Harvard University, Boston, MA, USA. 5MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK. 6Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 7Department of Biostatistics, University of Washington, Seattle, WA, USA. 8Medical Research Council, Banjul, The Gambia. 9Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA. 10Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. *To whom correspondence should be addressed: [email protected] or [email protected], Dauer Hall, PO Box 117450, Gainesville, FL 32611, USA. +1 (352) 294-1945 One Sentence Summary: As part of the WHO research and development Blueprint for action to prevent epidemics, we describe key considerations for the design and analysis of trials and studies to evaluate experimental vaccines during public health emergencies.
    [Show full text]